Does Mirabegron Have a Positive Impact on Sexual Function in Females With Overactive Bladder
NCT04511273 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2020-08-13
Summary
80 female patients evaluated for sexual function after receiving Mirabegron 50 mg once daily for 6 months for treatment of overactive bladder symptoms
Conditions
- Females With Overactive Bladder Symptoms, Urgency & Urge Incontinence
Interventions
- DRUG
-
Follow up of female sexual function
Mirabegron 50mg once daily for treatment of overactive bladder symptoms
Sponsors & Collaborators
-
Kasr El Aini Hospital
lead OTHER
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-09-01
- Primary Completion
- 2020-10-01
- Completion
- 2021-04-01
- FDA Drug
- Yes
More Related Trials
-
Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
NCT05452434 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
NCT04693897 ·Status: UNKNOWN
-
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT02981459 ·Status: WITHDRAWN ·Phase: PHASE4
-
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms
NCT04420533 ·Status: COMPLETED ·Phase: NA
-
Mirabegron and Urinary Urgency Incontinence
NCT02495389 ·Status: COMPLETED ·Phase: PHASE4
-
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 ·Status: COMPLETED
-
Predictors for Retreatement of OAB After DC Mirabegron
NCT04550702 ·Status: COMPLETED
-
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04562090 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
NCT05040984 ·Status: UNKNOWN
-
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
NCT03695822 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 ·Status: COMPLETED ·Phase: PHASE4
-
Management of OAB in Female Patients .
NCT06184334 ·Status: COMPLETED ·Phase: NA
-
Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
NCT02468375 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
NCT01638000 ·Status: COMPLETED ·Phase: PHASE3
-
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05188742 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02540707 ·Status: COMPLETED ·Phase: PHASE4
-
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
NCT05946902 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NCT01745094 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
NCT06181591 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug
NCT01627145 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
NCT07114640 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron
NCT03536494 ·Status: COMPLETED ·Phase: NA
-
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 ·Status: COMPLETED ·Phase: PHASE3
-
Prevalence And Risk Factors of Overactive Bladder Syndrome Among Egyptian Medical Students, and Their Impact On Health-Related Quality Of Life
NCT07044778 ·Status: COMPLETED